Ischemia and fibrosis: The risk mechanisms of hypertensive heart disease

Brazilian Journal of Medical and Biological Research

Volumn 33, Issue 6, 2000, Pages 693-700

  Frohlich, E D ^a  

^a OCHSNER MEDICAL CENTER   (United States)

Author keywords

Left ventricular hypertrophy; LVH; Myocardial ischemia; Risk factor; Ventricular fibrosis

Indexed keywords

CALCIUM ANTAGONIST; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE;

AGING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; DRUG MEGADOSE; FIBROSIS; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART VENTRICLE CONTRACTILITY; HUMAN; HYPERTENSION; ISCHEMIA; META ANALYSIS; PATHOPHYSIOLOGY; SALT INTAKE;

ANGINA;

EID: 0033945757     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2000000600010     Document Type: Conference Paper

References (61)

1. Frohlich ED (1988). The First Irvine H. Page Lecture: The mosaic of hypertension: Past, present, and future. Journal of Hypertension, 6: S2-S11.
2. Frohlich ED (1991). Is reversal of left ventricular hypertrophy in hypertension beneficial? Hypertension, 18 (Suppl I): 133-138.
3. Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V, Fauad-Tarazi F, Horan MJ, Marcus M, Massie B, Pfeffer MA, Re RN, Roccella EJ, Savage D & Shub C (1992). The heart in hypertension. New England Journal of Medicine, 327: 998-1008.
4. Pauletto P, Libera LD, Chem D, Vescovo G, Scannapieco G, Angelini A, Pessina AC & Palu CD (1985). Propranolol-induced changes in ventricular isomyosin composition in the rat. American Heart Journal, 109: 1269-1273.
5. Pringle SD, Dunn FG, McFarlane PW, McKillop JH, Lorimet AR & Cobbe SM (1992). Significance of ventricular arrhythmias in systemic hypertension with left ventricular hypertrophy. American Journal of Cardiology, 69: 913-917.
6. Dunn FG & Pringle SD (1993). Sudden cardiac death, ventricular arrhythmias and hypertensive left ventricular hypertrophy. Journal of Hypertension, 11: 1003-1010.
7. Haider AN, Larson MG, Benjamin EJ & Levy D (1998). Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. Journal of the American College of Cardiology, 32: 1454-1459.
8. Marcus ML, Duty DB, Hiratska LF, Wright CB & Eustham CL (1982). Decreased coronary reserve: A mechanism for angina pectoris in patients with aortic stenosis and normal coronary arteries. New England Journal of Medicine, 307: 1362-1367.
9. Opherk D, Nall G, Zebe H, Schwarz F, Weihe E, Manthy E & Kubler W (1984) Reduction of coronary reserve: A mechanism for angina pectoris in patients with arterial hypertension and normal coronary arteries. Circulation, 69: 1-7.
10. Scheler S, Wolfgang M & Strauer BE (1994). Mechanisms of angina pectoris with essential hypertension and normal epicardial arteries by arteriogram. American Journal of Cardiology, 73: 478-482.
11. Hamada M, Kuwahara T, Shigamatsu Y, Kodama K, Hara Y, Hashida H, Ikeda S, Ohstuka T, Nakata S & Hiwada K (1998). Relation between coronary blood flow and left ventricular mass in hypertension: Noninvasive quantification of coronary blood flow by thallium-201 myocardial scintigraphy. Hypertension Research, 21: 227-234.
12. Panza JA, Quyyami AA, Brush Jr JE & Epstein SE (1990). Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. New England Journal of Medicine, 323: 22-27.
13. Motz W, Vogt M, Rabenau D, Scheler S, Luokoff A & Strauer BD (1991). Evidence of endothelial dysfunction in coronary resistance vessels in patients with angina pectoris and normal coronary angiograms. American Journal of Cardiology, 68: 996-1003.
14. Treasure CB, Klein JC, Vita JA, Manoukian StV, Renwick GH, Selwin AP, Ganz P & Alexander RW (1993). Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary artery resistance vessels. Circulation, 87: 86-93.
15. Mulvany MJ (1992). Vascular growth in hypertension. Journal of Cardiovascular Pharmacology, 22: 7-11.
16. Nixenberg A & Antony I (1996). Epicardial coronary arteries are not adequately sized in hypertensive patients. Journal of the American College of Cardiology, 27: 1115-1123.
17. Chrysant SG, Frohlich ED, Adamopoulos PN, Stein PD, Whitcomb WH, Allen EW & Neller G (1976). Pathophysiological significance of "stress" or relative polycythemia in essential hypertension. American Journal of Cardiology, 31: 1069-1072.
18. Huysman JAN, Viegen HW, Vankerlaarse A & Eulderink F (1989), Changes in nonmyocyte tissue composition associated with pressure overload of hypertrophied human hearts. Pathology, Research and Practice, 184: 577-581.
19. Weber KT, Sun Y & Guarda E (1994). Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension, 23: 869-877.
20. Varo N, Etayo JC, Zalba G, Beaumont J, Iraburu MJ, Montiel C, Gil MJ, Monreal I & Diez J (1999) Losartan inhibits the post-transcriptional synthesis of collagen type 1 and reverses left ventricular fibrosis in spontaneously hypertensive rats Journal of Hypertension, 17: 107-114.
21. Collins C, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO & Hennekens CH (1990). Blood pressure, stroke and coronary heart disease. Part II Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet, 335: 827-838.
22. Siscovick DS, Raghunthan TE, Psaty BM, Koepsell TD, Wicklund KG, Lin X, Cobb L, Rautaharju PM, Copass MK & Wagner EH (1994). Diuretic therapy for hypertension and the risk of primary cardiac arrest. New England Journal of Medicine, 330: 1852-1857.
23. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (1997). The Sixth Report of the Joint National Committee (JNC-VI) on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Archives of Internal Medicine, 157: 2413-2446.
24. Swales JD (1994). Guidelines for treating hypertension In: Swales JD (Editor), Textbook of Hypertension. Blackwell Scientific Publications, Oxford, 1190-1221.
25. Thijs L, Fagard R, Lijuen F, Staessen J, Van Hoof R & Amery A (1992). A metaanalysis of outcome trials in elderly hypertensives. Journal of Hypertension, 10: 1103-1109.
26. Kannel WB, Gordon T & Offut D (1969). Left ventricular hypertrophy by electrocardiogram prevalence, incidence and mortality in the Framingham Study. Annals of Internal Medicine, 71: 99-105.
27. Schmieder RE, Martus P & Lkingbeil A (1996). Reversal of left ventricular hypertrophy in essential hypertension: A metaanalysis of randomized double-blind studies. Journal of the American Medical Association, 275: 1507-1513.
28. Re RN (1999). Hypothesis: The nature of intracrine peptide hormone action Hypertension, 34: 534-538.
29. Pringle SD, Dunn FD, Tweddel AC, Martin W, MacFarlane PW, McKillop JH, Lorimer AR & Cobbe SM (1992). Symptomatic and silent myocardial ischemia in hypertensive patients with left ventricular hypertrophy. British Heart Journal, 67: 377-382.
30. Nunez E, Hosoya K, Susic D & Frohlich ED (1997). Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR. Hypertension, 29: 519-524.
31. Metz W & Strauer BE (1996). Improvement of coronary flow reserve after long-term therapy with enalapril. Hypertension, 27: 1031-1038.
32. Balcells E, Meng QC, Johnson Jr WWH, Oparil S & Dell'Halia LJ (1997). Angiotensin II formation from ACE and chymase in human and animal hearts: Methods and species considerations. American Journal of Physiology, 273: H1769-H1774.
33. Linz W, Wiemer G, Golke P, Unger T & Sholkens BA (1995). Contribution of kinins on the cardiovascular action of angiotensin converting enzyme inhibitors. Pharmacological Reviews, 47: 25-29.
34. Frohlich ED (1997). Arthur C. Corcoran Memorial Lecture: Influence of nitric oxide and angiotensin II on renal involvement in hypertension. Hypertension, 29: 188-193.
35. Luscher TF (1994). The endothelium in hypertension: bystander, target or mediator? Journal of Hypertension, 12: 105-116.
36. Zeiher AM, Drexler H, Saurbrier B & Just H (1993). Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. Journal of Clinical Investigation, 92: 652-662
37. Anniken B-O, Holte HR & Berg T (1997). Amplification of kinin-induced hypertension by nitric oxide synthesis in spontaneously hypertensive rats. Hypertension, 29: 53-57.
38. Susic D & Frohlich ED (1999). Pharmacologic agents on cardiovascular mass and coronary hemodynamics in aging spontaneously hypertensive rats. Journal of Hypertension, 17: 1-7.
39. Susic D, Francischetti A & Frohlich ED (1999). Prolonged L-arginineon cardiovascular mass and myocardial hemodynamics and collagen in aged spontaneously hypertensive rats and normal rats. Hypertension, 33: 451-455.
40. Bottchen M, Botker HE, Sonne H, Nielsen TT & Czernin J (1999). Endothelium-dependent and -independent perfusion reserve and the effect of L-arginine on myocardial perfusion in patients wth syndrome X, Circulation, 99: 1795-1801.
41. McKee PA, Castelli WP, McNamara OM & Kannel WB (1971) The natural history of congestive heart failure. The Framingham Heart Study. New England Journal of Medicine, 285: 1441-1446.
42. Vasan RS, Benjamin EJ & Levy D (1995). Prevalence, clinical features and prognosis of diastolic heart failure: An epidemiologic perspective. Journal of the American College of Cardiology, 26: 1565-1574.
43. Frohlich ED, Tarazi RC &Dustan HP (1971). Clinical-physiological correlations in the development of hypertensive heart disease. Circulation, 44: 446-455.
44. Pfeffer MA, Pfeffer JM & Frohlich ED (1976). Pumping ability of the hypertrophying left ventricle of the spontaneously hypertensive rat. Circulation Research, 38: 423-429.
45. MacMahon SW, Cutler JA, Furberg CD & Payne GH (1989). The effects of drug treatment on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. Progress in Cardiovascular Diseases, 29: 99-118.
46. Topol EJ, Traill TA & Fortuin NJ (1985). Hypertensive hypertrophic cardiomyopathy of the elderly. New England Journal of Medicine, 312: 277-283.
47. Vasan RS & Levy D (1996), The role of hypertension in the pathogenesis of heart failure: A clinical mechanistic overview. Archives of Internal Medicine, 156: 1789-1796.
48. Shapiro LM & McKenna WJ (1984). Left ventricular hypertrophy relation of structure to diastolic function in hypertension. British Heart Journal, 51: 637-642.
49. Caspari PG, Newcomb M, Gibson K & Harris P (1977). Collagen in the normal and hypertrophied ventricle. Cardiovascular Research, 11: 554-558.
50. Susie D, Nunez E, Hosoya K & Frohlich ED (1998). Coronary hemodynamics in aging spontaneously hypertensive (SHR) and normotensive Wistar-Kyoto (WKY) rats. Journal of Hypertension, 16: 231-237.
51. Rossi MA (1998). Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. Journal of Hypertension, 16: 1031-1041.
52. Pegram BL, Ishise S & Frohlich ED (1982). Effect of methyldopa, clonidine, and hydralazine on cardiac mass and haemodynamics in Wistar Kyoto and spontaneously hypertensive rats. Cardiovascular Research, 16: 40-46.
53. Dunn FG, Ventura HO, Messerli FH, Kobrin I & Frohlich ED (1987). Time course of regression of left ventricular hypertrophy in hypertensive patients treated with atenolol. Circulation, 76: 254-258.
54. Amodeo C, Kobrin I, Ventura HO, Messerli FH & Frohlich ED (1986), Immediate and short-term hemodynamic effects of diltiazem in patients with hypertension. Circulation, 73: 108-113.
55. Frohlich ED, Sasaki O, Chien Y & Arita M (1992). Changes in cardiovascular mass, left ventricular pumping ability, and aortic distensibility after calcium antagonist in Wistar-Kyoto and spontaneously hypertensive rats. Journal of Hypertension, 10: 1369-1378.
56. Dunn FG, Oigman W, Ventura HO, Messerli FH, Kobrin I & Frohlich ED (1984). Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. American Journal of Cardiology, 53: 105-108.
57. Aristizabal D, Messerli FH & Frohlich ED (1994). Disparate structural effects of left and right ventricles by angiotensin converting enzyme inhibitors and calcium antagonists. American Journal of Cardiology, 73: 483-487.
58. Arita M, Honnaka S, Komatsu K & Frohlich ED (1993). Reversal of left ventricular hypertrophy with different classes of drugs causes differing ventricular biochemical changes. Journal of Hypertension, 11: S354-S355.
59. Mostero A, D'Agostino RB, Silbershatz H, Sytkowski PA, Kannel WB, Gobbee DE & Levy D (1999). Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. New England Journal of Medicine, 340: 1221-1227.
60. Frohlich ED, Chien Y, Sesoko S & Pegram BL (1993). Relationships between dietary sodium intake, hemodynamics and cardiac mass in spontaneously hypertensive and normotensive Wistar-Kyoto rats. American Journal of Physiology, 264: R30-R34.
61. Yu HCM, Burrell LM, Black MJ, Wu LL, Dilley RJ, Cooper ME & Johnston Cl (1998). Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation, 98: 2621-2628.